Viatris Reports Strong First-Quarter 2026 Performance with $3.5 Billion in Revenue

Viatris Reports Strong Performance for First Quarter of 2026

Viatris Inc. (Nasdaq: VTRS) has released its financial results for the first quarter of 2026, showcasing a total revenue of $3.5 billion. This figure marks an impressive 8% increase when compared to the same period in 2025. Additionally, the company's U.S. GAAP net earnings reached $176 million, a significant rebound from a substantial loss in the previous year.

Scott A. Smith, the CEO of Viatris, expressed his satisfaction with the company’s performance, stating, "We delivered a strong first quarter, reflecting disciplined execution across our global businesses." He added that this performance reinforces the growth trajectory the company had outlined during their Investor Event in March. Notable areas of growth included markets such as Greater China and North America, as the company made significant progress on various product launches and pipeline advancements.

Key Financial Highlights

In terms of operational metrics, Viatris reported total net sales of $3.509 billion, up 8% from the previous year. Notably, net sales from developed markets totaled $2.020 billion, reflecting a 7% increase. The company also saw robust performance in emerging markets, with a recorded growth totaling $535 million, despite certain supply chain challenges.

Moreover, adjusted EBITDA stood at $1.0 billion, a rise of 14% year-over-year. The adjusted earnings per share also saw a commendable increase of 18%, reaching $0.59 per share.

Launches and Pipeline Developments

One of the critical highlights mentioned in Viatris's report was the launch of Effexor® for the treatment of generalized anxiety disorder in Japan. Additionally, the company had six abstracts on its investigational low-dose estrogen weekly patch presented at the 2026 American College of Obstetricians and Gynecologists Annual Clinical Scientific Meeting, showcasing promising advancements in their contraceptive product pipeline.

Future Outlook

Viatris continues to anticipate generating more than $2.5 billion in cash available for deployment in 2026. The company reaffirmed its financial guidance, which estimates total revenues to be between $14.45 billion and $14.95 billion for the year. Adjusted EBITDA is expected in the range of $4.15 billion to $4.45 billion.

As Viatris moves forward, its management is focused on establishing a durable and higher-quality growth profile for the company. Scott A. Smith concluded, "Based on our strong start, we believe we are well positioned to deliver on our full-year guidance, while continuing our priority to build enduring solutions that address significant unmet needs in healthcare."

Investors and analysts eagerly await Viatris's continued performance as it navigates opportunities and challenges in the global healthcare landscape. The company is set to host a conference call later today to further dissect these results, making it an exciting time for stakeholders involved with Viatris.

Conclusion

Viatris’s strong financial performance in the first quarter of 2026 signifies a solid foundation for future growth, reinforced by strategic product launches and an emphasis on operational excellence. With an optimistic outlook for 2026, the company appears to be on a promising trajectory towards achieving its ambitious financial targets.